Last reviewed · How we verify
Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy — Treatment Landscape & Competitive Intelligence
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Abrocitinib 100 mg | abrocitinib-100-mg | Pfizer | Janus kinase inhibitor | JAK1 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy:
- Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy treatment updates — RSS
- Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy treatment updates — Atom
- Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy treatment updates — JSON
Cite this brief
Drug Landscape (2026). Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moderate-to-severe-atopic-dermatitis-in-children-aged-12-years-and-older-who-have-had-an-inadequate-response-or-intolerance-to-one-or-more-biologics-or-who-are-candidates-for-systemic-therapy. Accessed 2026-06-10.
Related
- Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing